发明名称 Quinoline derivatives having VEGF inhibiting activity
摘要 The invention relates to compounds of formula (I) wherein: either any one of G<SUB>1</SUB>, G<SUB>2</SUB>, G<SUB>3</SUB>, G<SUB>4 </SUB>and G<SUB>5 </SUB>is nitrogen and the other four are -CH-, or G<SUB>1</SUB>, G<SUB>2</SUB>, G<SUB>3</SUB>, G<SUB>4 </SUB>and G<SUB>5 </SUB>are all -CH-; Z is -O-, -NH-, -S-, -CH<SUB>2</SUB>- or a direct bond; Z is linked to any one of G<SUB>1</SUB>, G<SUB>2</SUB>, G<SUB>3 </SUB>and G<SUB>4</SUB>; n is an integer from 0 to 5; m is an integer from 0 to 3; R<SUP>a </SUP>represents hydrogen or fluoro; R<SUP>b</SUP>, R<SUP>1 </SUP>and R<SUP>2 </SUP>are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.
申请公布号 US7371765(B2) 申请公布日期 2008.05.13
申请号 US20030332274 申请日期 2003.01.07
申请人 ASTRAZENECA AB 发明人 HENNEQUIN LAURENT FRANCOIS ANDRE
分类号 A61K31/47;A01N43/42;A61K31/4709;A61K31/496;A61K31/497;A61K31/54;A61K31/541;A61P3/10;A61P9/00;A61P9/10;A61P13/12;A61P15/00;A61P17/06;A61P27/02;A61P29/00;A61P35/00;A61P37/02;A61P43/00;C07D215/00;C07D215/38;C07D279/10;C07D279/12;C07D295/00;C07D401/00;C07D401/12;C07D401/14;C07D405/14;C07D417/14 主分类号 A61K31/47
代理机构 代理人
主权项
地址